{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T08:22:59Z","timestamp":1794298979593,"version":"4.9.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T00:00:00Z","timestamp":1592784000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T00:00:00Z","timestamp":1592784000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Antipsychotic drugs target primarily dopaminergic system which makes catechol-<jats:italic>O<\/jats:italic>-methyltransferase (COMT) an interesting target in studies searching for treatment response predictors in schizophrenia. The study assessed the association of the <jats:italic>COMT<\/jats:italic> rs4680 and rs4818 polymorphisms with therapeutic response to olanzapine, risperidone, clozapine or other antipsychotic medication after 8\u00a0weeks of monotherapy in patients with schizophrenia. 521 Caucasian patients with schizophrenia received a monotherapy with olanzapine (10\u201320\u00a0mg\/day; N\u2009=\u2009190), risperidone (3\u20136\u00a0mg\/day; N\u2009=\u200999), or clozapine (100\u2013500\u00a0mg\/day; N\u2009=\u2009102). The fourth group (N\u2009=\u2009130) consisted of patients receiving haloperidol (3\u201315\u00a0mg\/day), fluphenazine (4\u201325\u00a0mg\/day) or quetiapine (50\u2013800\u00a0mg\/day). Treatment response was defined as a 50% reduction from the baseline positive and negative syndrome scale (PANSS) total and subscale scores, but also as an observed percentage reduction from the initial PANSS<jats:sub>0\u20136<\/jats:sub> total and subscale scores. Carriers of the <jats:italic>COMT<\/jats:italic> rs4680 A allele and carriers of the <jats:italic>COMT<\/jats:italic> rs4680\u2013rs4818 C-A haplotype block had greater reduction in the PANSS total scores following olanzapine treatment, compared to carriers of the <jats:italic>COMT<\/jats:italic> rs4680 GG genotype and other <jats:italic>COMT<\/jats:italic> rs4680\u2013rs4818 haplotypes. The <jats:italic>COMT<\/jats:italic> rs4680 A allele, and <jats:italic>COMT<\/jats:italic> rs4680\u2013rs4818 C-A haplotype, were significantly associated with therapeutic response in patients treated with olanzapine, but not in patients treated with other antipsychotics.<\/jats:p>","DOI":"10.1038\/s41598-020-67351-5","type":"journal-article","created":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T10:03:36Z","timestamp":1592820216000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia"],"prefix":"10.1038","volume":"10","author":[{"given":"Matea","family":"Nikolac Perkovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Sagud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Zivkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzana","family":"Uzun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordana","family":"Nedic Erjavec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Kozumplik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dubravka","family":"Svob Strac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninoslav","family":"Mimica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma","family":"Mihaljevic Peles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nela","family":"Pivac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,22]]},"reference":[{"key":"67351_CR1","doi-asserted-by":"crossref","unstructured":"Huang, E. et al. Catechol-O-methyltransferase Val158Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizo-affective disorder patients: a meta-analysis. Int. J. Neuropsychopharmacol. 19, pyv132 (2016).","DOI":"10.1093\/ijnp\/pyv132"},{"key":"67351_CR2","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.1021\/bi00013a008","volume":"34","author":"T Lotta","year":"1995","unstructured":"Lotta, T. et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34, 4202\u20134210 (1995).","journal-title":"Biochemistry"},{"key":"67351_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1126\/science.758679","volume":"203","author":"PD Scanlon","year":"1979","unstructured":"Scanlon, P. D., Raymond, F. A. & Weinshilboum, R. M. Catechol-O-methyltransferase: thermolabile enzyme in erythrocytes of subjects homozygous for allele for low activity. Science 203, 63\u201365 (1979).","journal-title":"Science"},{"key":"67351_CR4","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.biopsych.2019.05.014","volume":"86","author":"EM Tunbridge","year":"2019","unstructured":"Tunbridge, E. M. et al. Which dopamine polymorphisms are functional? Systematic review and meta-analysis of COMT, DAT, DBH, DDC, DRD1-5, MAOA, MAOB, TH, VMAT1, and VMAT2. Biol. Psychiatry 86, 608\u2013620 (2019).","journal-title":"Biol. Psychiatry"},{"key":"67351_CR5","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.neuropsychologia.2007.10.009","volume":"46","author":"P Roussos","year":"2008","unstructured":"Roussos, P., Giakoumaki, S. G., Pavlakis, S. & Bitsios, P. Planning, decision-making and the COMT rs4818 polymorphism in healthy males. Neuropsychologia 46, 757\u2013763 (2008).","journal-title":"Neuropsychologia"},{"key":"67351_CR6","doi-asserted-by":"crossref","unstructured":"Yoshida, K. & M\u00fcller, D. J. Pharmacogenetics of antipsychotic drug treatment: update and clinical implications. Mol. Neuropsychiatry 1\u201326, doi: 10.1159\/000492332 (2018).","DOI":"10.1159\/000492332"},{"key":"67351_CR7","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3389\/fphar.2018.00705","volume":"9","author":"M Sagud","year":"2018","unstructured":"Sagud, M. et al. Haplotypic and Genotypic Association of Catechol-O-Methyltransferase rs4680 and rs4818 Polymorphisms and Treatment Resistance in Schizophrenia. Front. Pharmacol. 9, 705 (2018).","journal-title":"Front. Pharmacol."},{"key":"67351_CR8","first-page":"127","volume":"28","author":"T Terzic","year":"2016","unstructured":"Terzic, T., Kastelic, M., Dol\u017ean, V. & Plesni\u010dar, B. K. Genetic polymorphisms in dopaminergic system and treatment-resistant schizophrenia. Psychiatr. Danub. 28, 127\u2013131 (2016).","journal-title":"Psychiatr. Danub."},{"key":"67351_CR9","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.psychres.2019.04.028","volume":"279","author":"M Zivkovic","year":"2019","unstructured":"Zivkovic, M. et al. The lack of association between COMT rs4680 polymorphism and symptomatic remission to olanzapine monotherapy in male schizophrenic patients: a longitudinal study. Psychiatry Res. 279, 389\u2013390 (2019).","journal-title":"Psychiatry Res."},{"key":"67351_CR10","first-page":"270","volume":"22","author":"M Sagud","year":"2010","unstructured":"Sagud, M. et al. Catechol-O-methyl transferase and schizophrenia. Psychiatr. Danub. 22, 270\u2013274 (2010).","journal-title":"Psychiatr. Danub."},{"key":"67351_CR11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2217\/14622416.10.3.385","volume":"10","author":"M Gupta","year":"2009","unstructured":"Gupta, M. et al. Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics 10, 385\u2013397 (2009).","journal-title":"Pharmacogenomics"},{"key":"67351_CR12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0924-977X(02)00176-1","volume":"13","author":"A Illi","year":"2003","unstructured":"Illi, A. et al. Interaction between angiotensin-converting enzyme and catechol-O-methyltranferase genotypes in schizophrenics with poor response to conventional neuroleptics. Eur. Neuropsychopharmacol. 13, 147\u2013151 (2003).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"67351_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/hup.841","volume":"22","author":"A Illi","year":"2007","unstructured":"Illi, A. et al. Catechol-O-methyltransferase val108\/158met genotype and response to antipsychotic medication in schizophrenia. Hum. Psychopharmacol. 22, 211\u2013215 (2007).","journal-title":"Hum. Psychopharmacol."},{"key":"67351_CR14","doi-asserted-by":"crossref","unstructured":"Inada, T., Nakamura, A. & Iijima, Y. Relationship between catechol-O-methyltransferase polymorphism and treatment-resistant schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 120B, 35\u201339 (2003).","DOI":"10.1002\/ajmg.b.20023"},{"key":"67351_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.psychres.2014.05.039","volume":"219","author":"P Tybura","year":"2014","unstructured":"Tybura, P. et al. Pharmacogenetics of adverse events in schizophrenia treatment: Comparison study of ziprasidone, olanzapine and perazine. Psychiatry Res. 219, 261\u2013267 (2014).","journal-title":"Psychiatry Res."},{"key":"67351_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.euroneuro.2012.01.006","volume":"22","author":"J Vehof","year":"2012","unstructured":"Vehof, J. et al. Clinical response to antipsychotic drug treatment: association study of polymorphisms in six candidate genes. Eur. Neuropsychopharmacol. 22, 625\u2013631 (2012).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"67351_CR17","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1097\/YIC.0b013e328338b884","volume":"25","author":"NA Kocabas","year":"2010","unstructured":"Kocabas, N. A. et al. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case\u2013control association study. Int. Clin. Psychopharmacol. 25, 218\u2013227 (2010).","journal-title":"Int. Clin. Psychopharmacol."},{"key":"67351_CR18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","volume":"162","author":"NC Andreasen","year":"2005","unstructured":"Andreasen, N. C. et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiat. 162, 441\u2013449 (2005).","journal-title":"Am. J. Psychiat."},{"key":"67351_CR19","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1600-0447.2008.01308.x","volume":"119","author":"S Leucht","year":"2009","unstructured":"Leucht, S., Davis, J. M., Engel, R. R., Kissling, W. & Kane, J. M. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr. Scand. 119, 7\u201314 (2009).","journal-title":"Acta Psychiatr. Scand."},{"key":"67351_CR20","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/sj.tpj.6500441","volume":"7","author":"P Molero","year":"2007","unstructured":"Molero, P., Ortu\u00f1o, F., Zalacain, M. & Pati\u00f1o-Garc\u00eda, A. Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment. Pharmacogenomics J. 7, 418\u2013426 (2007).","journal-title":"Pharmacogenomics J."},{"key":"67351_CR21","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.biopsych.2004.06.038","volume":"56","author":"NC Stefanis","year":"2004","unstructured":"Stefanis, N. C. et al. Variation in catechol-o-methyltransferase val158 met genotype associated with schizotypy but not cognition: a population study in 543 young men. Biol. Psychiatry 56, 510\u2013515 (2004).","journal-title":"Biol. Psychiatry"},{"key":"67351_CR22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.schres.2007.06.014","volume":"95","author":"A Bertolino","year":"2007","unstructured":"Bertolino, A. et al. COMT Val158Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia. Schizophr. Res. 95, 253\u2013255 (2007).","journal-title":"Schizophr. Res."},{"key":"67351_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/00008571-200405000-00005","volume":"14","author":"S Anttila","year":"2004","unstructured":"Anttila, S. et al. Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics. Pharmacogenetics 14, 303\u2013307 (2004).","journal-title":"Pharmacogenetics"},{"key":"67351_CR24","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/tpj.2009.24","volume":"9","author":"BA Fijal","year":"2009","unstructured":"Fijal, B. A. et al. Candidate-gene association analysis of response to risperidone in African American and white patients with schizophrenia. Pharmacogenomics J. 9, 311\u2013318 (2009).","journal-title":"Pharmacogenomics J."},{"key":"67351_CR25","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.biopsych.2004.08.012","volume":"56","author":"TW Weickert","year":"2004","unstructured":"Weickert, T. W. et al. Catechol-O-methyltransferase val108\/158met genotype predicts working memory response to antipsychotic medications. Biol. Psychiatry 56, 677\u2013682 (2004).","journal-title":"Biol. Psychiatry"},{"key":"67351_CR26","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.schres.2006.10.002","volume":"90","author":"ND Woodward","year":"2007","unstructured":"Woodward, N. D., Jayathilake, K. & Meltzer, H. Y. COMT val108\/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr. Res. 90, 86\u201396 (2007).","journal-title":"Schizophr. Res."},{"key":"67351_CR27","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/YPG.0b013e328358629a","volume":"22","author":"QZ Zhao","year":"2012","unstructured":"Zhao, Q. Z. et al. Association between a COMT polymorphism and clinical response to risperidone treatment: a pharmacogenetic study. Psychiatr. Genet. 22, 298\u2013299 (2012).","journal-title":"Psychiatr. Genet."},{"key":"67351_CR28","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.2147\/NDT.S164647","volume":"14","author":"H Kaneko","year":"2018","unstructured":"Kaneko, H. et al. COMT Val 108\/158 Met polymorphism and treatment response to aripiprazole in patients with acute schizophrenia. Neuropsychiatr. Dis. Treat. 14, 1657\u20131663 (2018).","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"67351_CR29","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2217\/pgs.14.150","volume":"16","author":"M Bosia","year":"2015","unstructured":"Bosia, M. et al. COMT Val158Met and 5-HT1A-R \u20131019 C\/G polymorphisms: effects on the negative symptom response to clozapine. Pharmacogenomics 16, 35\u201344 (2015).","journal-title":"Pharmacogenomics"},{"key":"67351_CR30","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.2147\/NDT.S176455","volume":"14","author":"R Escamilla","year":"2018","unstructured":"Escamilla, R. et al. Association study between COMT, DRD2, and DRD3 gene variants and antipsychotic treatment response in Mexican patients with schizophrenia. Neuropsychiatr. Dis. Treat. 14, 2981\u20132987 (2018).","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"67351_CR31","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.euroneuro.2012.12.002","volume":"23","author":"Y Gong","year":"2013","unstructured":"Gong, Y. et al. Polymorphisms in microRNA target sites influence susceptibility to schizophrenia by altering the binding of miRNAs to their targets. Eur. Neuropsychopharmacol. 23, 1182\u20131189 (2013).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"67351_CR32","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1126\/science.1131262","volume":"314","author":"AG Nackley","year":"2006","unstructured":"Nackley, A. G. et al. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 314, 1930\u20131933 (2006).","journal-title":"Science"},{"key":"67351_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/FPC.0000000000000314","volume":"28","author":"VM Rajagopal","year":"2018","unstructured":"Rajagopal, V. M., Rajkumar, A. P., Jacob, K. S. & Jacob, M. Gene-gene interaction between DRD4 and COMT modulates clinical response to clozapine in treatment-resistant schizophrenia. Pharmacogenet. Genomics 28, 31\u201335 (2018).","journal-title":"Pharmacogenet. Genomics"},{"key":"67351_CR34","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.biopsych.2017.06.033","volume":"82","author":"EC Johnson","year":"2017","unstructured":"Johnson, E. C. et al. No evidence that schizophrenia candidate genes are more associated with schizophrenia than non-candidate genes. Biol Psychiatry. 82, 702\u2013708 (2017).","journal-title":"Biol Psychiatry."},{"key":"67351_CR35","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1007\/s11920-011-0184-4","volume":"13","author":"R Sherva","year":"2011","unstructured":"Sherva, R. & Farrer, L. A. Power and pitfalls of the genome-wide association study approach to identify genes for Alzheimer\u2019s disease. Curr. Psychiatry. Rep. 13, 138\u2013146 (2011).","journal-title":"Curr. Psychiatry. Rep."},{"key":"67351_CR36","first-page":"76","volume":"59","author":"EJ Brandl","year":"2014","unstructured":"Brandl, E. J., Kennedy, J. L. & M\u00fcller, D. J. Pharmacogenetics of antipsychotics. Can. J. Psychiatry 59, 76\u201388 (2014).","journal-title":"Psychiatry"},{"key":"67351_CR37","doi-asserted-by":"crossref","unstructured":"Nikolac Perkovic, M. et al. Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients. Psychopharmacology 231, 3757\u20133764 (2014).","DOI":"10.1007\/s00213-014-3515-4"},{"key":"67351_CR38","volume-title":"Structured clinical interview for DSM-IV-patient edition (SCID-P)","author":"MB First","year":"1995","unstructured":"First, M. B., Spitzer, R. L., Williams, J. B. W. & Gibbons, M. Structured clinical interview for DSM-IV-patient edition (SCID-P) (American Psychiatric Press, Washington, DC, 1995)."},{"key":"67351_CR39","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay, S. R., Fisbein, A. & Opler, L. A. The Positive and negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 13, 261\u2013276 (1987).","journal-title":"Schizophr. Bull."},{"key":"67351_CR40","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","volume":"16","author":"SA Miller","year":"1988","unstructured":"Miller, S. A., Dykes, D. D. & Polesky, H. F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16, 1215 (1988).","journal-title":"Nucleic Acids Res."},{"key":"67351_CR41","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1093\/aje\/kwn359","volume":"169","author":"S Rodriguez","year":"2009","unstructured":"Rodriguez, S., Gaunt, T. R. & Day, I. N. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am. J. Epidemiol. 169, 505\u2013514 (2009).","journal-title":"Am. J. Epidemiol."},{"key":"67351_CR42","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/bioinformatics\/bth457","volume":"21","author":"JC Barrett","year":"2005","unstructured":"Barrett, J. C., Fry, B., Maller, J. & Daly, M. J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263\u2013265 (2005).","journal-title":"Bioinformatics"},{"key":"67351_CR43","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1086\/519795","volume":"8","author":"S Purcell","year":"2007","unstructured":"Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 8, 559\u2013575 (2007).","journal-title":"Am. J. Hum. Genet."},{"key":"67351_CR44","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3758\/BF03193146","volume":"39","author":"F Faul","year":"2007","unstructured":"Faul, F., Erdfelder, E., Lang, A. G. & Buchner, A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods 39, 175\u2013191 (2007).","journal-title":"Behav. Res. Methods"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67351-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67351-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67351-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T12:32:57Z","timestamp":1670329977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-67351-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,22]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["67351"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-67351-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,22]]},"assertion":[{"value":"19 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10049"}}